Brief: Heron Therapeutics Announces FDA Approval Of Zynrelef® Indication Expansion To Include Additional Orthopedic And Soft Tissue Procedures
24/01/2024 01:06
Jan 23 (Reuters) - Heron Therapeutics Inc HRTX.O :
* HERON THERAPEUTICS ANNOUNCES FDA APPROVAL OF ZYNRELEF®
INDICATION EXPANSION TO INCLUDE ADDITIONAL ORTHOPEDIC AND SOFT
TISSUE PROCEDURES
* HERON THERAPEUTICS INC - EXPANDED INDICATION FOR ZYNRELEF
NOW
COVERS APPROXIMATELY 13 MILLION PROCEDURES ANNUALLY
Source text for Eikon: ID:nPnc9XThNa
Further company coverage: HRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop